NCT02011113View on ClinicalTrials.gov

Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2015

Conditions
Multiple Myeloma
Interventions
DRUG

Pomalidomide

4 mg oral pomalidomide once daily Days 1-21 of each 28-day cycle

DRUG

Dexamethasone

40 mg or 20 mg oral dexamethasone once daily on Days 1, 8, 15, 22 of each 28-day cycle

Trial Locations (14)

467-8602

Celgene Trial Site, Nagoya

298-8602

Celgene Trial Site, Kamogawa

812-8582

Celgene Trial Site, Fukuoka

734-8551

Celgene Trial Site, Hiroshima

311-3193

Celgene Trial Site, Mito

259-1193

Celgene Trial Site, Isehara

602-8566

Celgene Trial Site, Kyoto

951-8566

Celgene Trial Site, Niigata

701-1192

Celgene Trial Site, Okayama

543-8555

Celgene Trial Site, Osaka

104-0045

Celgene Trial Site, Tokyo

150-8935

Celgene Trial Site, Tokyo

160-8582

Celgene Trial Site, Tokyo

162-8655

Celgene Trial Site, Tokyo

Sponsors
All Listed Sponsors
lead

Celgene Corporation

INDUSTRY